biologics treatment
ApprovedBiologic
biologics treatment is one of 51 biologic programs targeting Psoriatic Arthritis. It is currently in Approved.
1
Indications
1
Total Trials
1
Active Trials
50
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
114 competitors in Psoriatic Arthritis
#DrugCompanyPhaseTrials
1Bimzelx
UCBPhase 3
Skyrizi
AbbViePhase 3
Jyseleca
GileadPhase 3
Taxol
TevaPhase 3
Keytruda
Merck & Co.Phase 3
Icotyde
Johnson & JohnsonPhase 3
Xeljanz
PPrism Pharmaceuticals
Phase 3
Sotyktu
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for biologics treatment. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details